


INTRODUCTION

- Quercetin in combination with polyvinylpyrrolidone (PVP) was found to limit the spreading of necrosis to unaffected tissues in tuberculosis infected mice. Therefore, we hypothesized that 3D printed medicated skin patch incorporated with quercetin-PVP concentration would provide an appropriate therapeutic drug concentration with desired sustained release profile.
- We fabricated quercetin-PVP bio-filaments by hot melt extrusion (HME) technique along with Eudragit® RSPO and tri-ethyl citrate as plasticizer and further 3D printed it to make medicated skin patches using fused deposition modelling (FDM). Various characterizations were performed to optimize the 3D printed patch formulation.

METHODOLOGY



Sample Code	Quercetin (%w/w)	PVP 40 (%w/w)	Eudragit® RS PO (%w/w)	TEC (%w/w)	Total Weight (%w/w)
T ₁	1.0	49.0	38.0	12.0	100
T ₂	1.0	37.0	50.0	12.0	100
T ₃	1.0	25.0	62.0	12.0	100
T ₄	0.0	50.0	38.0	12.0	100
T ₅	0.0	38.0	50.0	12.0	100
T ₆	0.0	26.0	62.0	12.0	100

Table 1: Formulation design table for 3D patches



Figure 1 Fabrication of (A) Quercetin-loaded filament, (B) Blank filament and (C) 3D printed patch.

RESULTS AND DISCUSSION

Code	% Loading of filament	% Entrapment of 3D patch
T ₁	101.30 ± 1.57	96.56 ± 3.19
T ₂	102.05 ± 2.40	98.11 ± 4.08
T ₃	125.97 ± 3.00	86.55 ± 4.88

Table 2: Percentage loading & entrapment values of quercetin

Pharmacokinetic Parameters	Quercetin Value
C _{max} (µg/ml)	2.07 (±0.05)
t _{max} (h)	328 (±13.86)
AUC _{0-t} (µg.h/ml)	368.11 (±12.71)
AUMC _{0-t} (µg.h ² /ml)	122712.53 (±3829.21)
k _{el} (h ⁻¹)	0.00092 (±0.0005)
T _{1/2} (h)	1025.09 (±771.31)
MRT (h)	333.38 (±1.30)

Table 3: PK parameters of quercetin (n = 3)




Figure 3 DSC thermograms




Figure 4 X-ray diffractogram




Figure 5 In vitro quercetin release (n=3)

Figure 2 SEM micrograph of fabricated 3D patch





Figure 6 PK profile of quercetin in rat (n = 3).

CONCLUSION

Overall data confirmed the feasibility of developing 3D printed medicated skin patches to provide plasma levels for continued 18 days in rats after a single application.

ACKNOWLEDGEMENT

All the author's sincerely acknowledges the financial support of **S&T Division, ASTE Council** by Department of Science & Technology (DST), Government of Assam under **ITGA-2019** scheme vide F.No ASTEC/S&T/1614/8/2018-19/1151 for the project titled "**Medicated Skin Patch to mitigate destructive pulmonary tuberculosis in six districts of Assam**".

REFERENCES

❖ **Subham Banerjee**, Vishal Sharad Chaudhari, Tushar Kanti Malakar, USN Murty. "Medicated skin patch, use and method of making thereof." Application No. 202031018293. FER Response Filed: 4 Sept, 2020, FER Issued: 28 May, 2020, Published: 15 May, 2020, Date of Filing: 29 April, 2020.